James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Is MGM Resorts International (MGM) Stock the Best Casino Bet?

MGM stock is up 50% since last February, but JPMorgan says there's another 36% upside if Macau continues to recover.

Why Hibbett Sports, Inc. (HIBB), Northern Dynasty Minerals Ltd (NAK) and FLIR Systems, Inc. (FLIR) Are 3 of Today’s Worst Stocks

FLIR Systems (FLIR), Hibbett Sports (HIBB) and Northern Dynasty Minerals (NAK) couldn't win for losing on Tuesday.

Red Flags are Waving in the Last Place We Want Them

The S&P 500 may still be making gains, but those gains are getting tougher to make, and we saw some serious problems start to surface Monday.

Why Nvidia Corporation (NVDA), T-Mobile US Inc (TMUS) and Hain Celestial Group Inc (HAIN) Are 3 of Today’s Worst Stocks

Nvidia (NVDA), T-Mobile (TMUS) and Hain Celestial Group (HAIN) shareholders were all wishing the weekend lasted on more day.

9 Top Pharmaceutical Stocks to Buy for the Dividends

Fans of dividends don't have to completely abandon all hope for growth too -- these top pharmaceutical stocks offer the best of both worlds.